3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
55
Endometrial Neoplasms
7
Ovarian Neoplasms
5
Neoplasm Metastasis
5
Polycystic Ovary Syndrome
4
Neoplasms
4
Advanced Breast Cancer
4
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Carcinoma, Intraductal, Noninfiltrating
3
Recurrence
2
Neoplasms by Site
2
Infertility
2
HR+/HER2- Breast Cancer
2
Estrogen Receptor-positive Breast Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms, Male
2
Breast Diseases
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sexual Dysfunctions, Psychological
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Low-Grade Serous Ovarian Cancer
1
Low Grade Serous Ovarian Carcinoma
1
Low Grade Serous Ovarian Cancer
1
Locoregional Recurrence
1
Leiomyoma
1
Interventions
Fulvestrant
4
ribociclib
2
palbociclib
2
Irinotecan
2
Gemcitabine
2
venetoclax
1
tivozanib
1
serabelisib
1
sapanisertib
1
niraparib
1
lorlatinib
1
liposomal doxorubicin
1
inavolisib
1
exemestane
1
encorafenib
1
cemiplimab
1
binimetinib
1
abemaciclib
1
Taxes
1
Tamoxifen
1
STX-478
1
Paclitaxel
1
Metformin
1
Lomustine
1
Letrozole
1
Imlunestrant
1
Doxorubicin
1
Cetuximab
1
Carboplatin
1
CA-4948
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Letrozole
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled